Tuesday - December 16, 2025
Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-Positive Early-Stage Breast Cancer
December 11, 2025
SOUTH SAN FRANCISCO, California, Dec. 11 -- Genentech, a member of Roche Group, issued the following news release:

* * *

Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-Positive Early-Stage Breast Cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years

Transformationa . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products